Why “AI Fluency” Is Becoming a Core Skill in Australia’s Life Sciences Workforce
Across Australia’s biotech, medtech, pharmaceutical and CRO sectors, artificial intelligence (AI) is no longer an abstract R&D concept or a specialist capability reserved for data science teams. Increasingly, the ability to use AI tools and agents is becoming a highly sought‑after skillset across scientific, clinical, regulatory and commercial roles.
This shift reflects a broader reality playing out across the Australian economy: AI adoption is being driven by users embedded in real‑world workflows, not by a sudden expansion of highly technical AI engineering roles. For life sciences organisations, where funding and capital are often limited, regulatory expectations are high and timelines are long, productivity‑enhancing AI tools are becoming essential, and we’re starting to see more evidence of this in our discussions with companies in this space.
Australia’s AI Transition is User‑led, not Developer‑led
Government and industry data consistently shows that Australia’s AI ecosystem is primarily focused on adoption and integration, rather than frontier model development. The National Artificial Intelligence Centre’s Australia’s Artificial Intelligence Ecosystem: Growth and Opportunities report (June 2025) describes Australia as a hybrid “AI‑taker and selective AI‑maker” economy, where value creation largely comes from embedding AI into existing industries, including chemicals, manufacturing and health sciences.
This distinction matters for life sciences employers. It signals that demand will not be limited to machine learning engineers or data scientists, but will increasingly extend to professionals who can:
- interact confidently with AI tools,
- interrogate outputs critically,
- understand limitations, bias and regulatory implications, and
- translate AI‑generated insights into scientific, clinical or business decisions.
Jobs and Skills Australia’s Generative AI Capacity Study (August 2025) reinforces this point, finding that generative AI is far more likely to augment existing roles than replace them, with many workers already using AI tools independently in their day‑to‑day work.
This is reinforced by the buy-in we’re seeing from AI developers, the most recent example of which is the MOU signing between the Australian Government and Anthropic, who – reflecting their belief the potential for AI to benefit our local Life Sciences ecosystem – recently announced a $3M (in ‘Claude credits’) investment in AI applications for companies operating within the research and innovation sectors that could benefit from AI deployment [9].
Life Sciences are Already Among the Most AI‑Exposed Sectors
While the financial services and IT & communications sectors often dominate AI headlines, health‑adjacent industries are among the most exposed to AI augmentation in practice. PwC’s AI Jobs Barometer 2025 shows that Human Health and Social Work Activities steadily increased their share of AI‑exposed job postings through 2024, reaching over 11% of Australian AI‑related roles.
Crucially, PwC’s data also highlights that AI‑exposed jobs are not declining. Instead, they are evolving faster, with required skills changing 66% more quickly than in non‑AI‑exposed roles, and AI‑skilled workers commanding significant wage premiums.
For biotech, medtech, pharma and CROs, this translates to growing demand for professionals who can work with:
- AI‑assisted literature and evidence review tools,
- clinical trial feasibility and patient recruitment platforms,
- AI‑enabled imaging and diagnostic software,
- automated regulatory documentation systems, and
- pharmacovigilance and real‑world evidence tools.
Medtech and Healthcare: Capability Uplift over Algorithm Development
Australia’s medtech sector has been particularly explicit about where the real bottleneck lies. In November 2025, APACMed/MTAA released their AI Revolutionising MedTech Symposium Report, which concluded that Australia’s largest constraint is not algorithm availability, but workforce readiness and workflow redesign. Industry leaders repeatedly emphasised the need to empower clinicians and operational teams to integrate AI into existing care pathways and decision‑making processes.
Similarly, the Australasian Institute of Digital Health’s AI Workforce Insights Paper 2024 stresses that healthcare and life sciences workers do not need to be AI developers, but must understand what AI is, how it works at a high level, its limitations, and how to explain its outputs safely and transparently to colleagues, regulators and patients.
These findings align closely with medtech and diagnostics roles in Australia, where regulatory accountability sits squarely with human decision‑makers, even (perhaps especially) when AI systems are involved.
CROs and Pharma: Productivity Pressure Accelerates AI Tool Adoption
In pharma and CRO environments, AI adoption is increasingly driven by operational pressure rather than innovation ambition. Australia’s pharmaceutical R&D intensity rose by more than 20% between 2020 and 2023 [5], while talent shortages persist across clinical data management, regulatory affairs and trial operations. Industry analyses consistently identify skills gaps, not technology gaps, as the main barrier to scaling AI in pharma [6,7].
As a result, organisations are prioritising upskilling existing staff to use AI‑enabled tools for:
- protocol drafting and review,
- clinical data cleaning and analysis,
- safety signal detection,
- medical writing and publications support, and
- commercial and launch planning.
Importantly, PwC notes that companies adopting AI successfully are seeing productivity gains without reducing headcount, reinforcing that AI literacy is becoming a way to make life sciences professionals more valuable, not redundant [3]. Companies like Algorae – which, at the end of March, officially announced details of its AI drug screening validation program – are clear examples of this – and it’s exciting to see Australia competing on the global stage [10].
From “Nice to Have” to Baseline Professional Capability
What is emerging across reports and industry commentary is a clear shift in expectations. The Tech Council of Australia’s Meeting the AI Skills Boom report (2024) forecasts up to 200,000 AI‑related roles by 2030, the majority of which are non‑technical roles requiring AI‑adjacent competence rather than development skills.
In Australia’s life sciences sector, this means AI fluency is fast becoming:
- a baseline employability skill for scientists, clinicians and regulatory professionals;
- a differentiator for leaders responsible for productivity and governance; and
- a prerequisite for organisations seeking to scale without proportionally growing headcount.
Looking Ahead
For biotech, medtech, pharma and CRO organisations operating in Australia’s highly regulated, resource‑constrained environment, the message is clear. Competitive advantage will not come from building bespoke AI models in‑house, but from cultivating a workforce that can confidently, critically and responsibly use AI tools already available to them.
As AI capabilities continue to embed themselves into laboratory software, trial platforms, regulatory workflows and decision‑support systems, organisations that treat AI fluency as a core professional skill will be far better positioned to attract talent, improve productivity and remain globally competitive.
References
- Australian Government, National Artificial Intelligence Centre (June 25, 2025). “Australia’s artificial intelligence ecosystem: growth and opportunities.” Accessed online at https://www.industry.gov.au/publications/australias-artificial-intelligence-ecosystem-growth-and-opportunities
- Australian Government, Jobs and Skills Australia (August 14, 2025). “Our Gen AI Transition – Implications for Work and Skills.” Accessed online at https://www.jobsandskills.gov.au/publications/generative-ai-capacity-study-report
- PricewaterhouseCoopers (July 2025). “The Fearless Future: 2025 Global AI Jobs Barometer – Australia Analysis.” Accessed online at https://www.pwc.com/gx/en/issues/artificial-intelligence/job-barometer/aijb-2025-australia-analysis.pdf
- APACMed & Medical Technology Association of Australia (February 3, 2026). “AI Revolutionising Medtech Symposium Australia – Summary Report.” Accessed online at https://apacmed.org/wp-content/uploads/2026/02/AI-Revolution-Australia-Report-v2.pdf
- Organisation for Economic Co-operation and Development (ongoing/live dataset). “Science, Technology and Innovation Scoreboard.” Accessed online at https://www.oecd.org/en/data/datasets/science-technology-and-innovation-scoreboard.html
- Florian Marthaler, on behalf of Talenbrium (May 11, 2025). “Australia Top 30 Trending Roles in the Pharma & Biotech Industry: Strategic Workforce Planning, Hiring Trends, In Demand Skillsets, Demand Push, Salary Benchmarking, Job Demand and Supply: 2025 Edition.” Accessed online at https://www.talenbrium.com/report/australia-top-30-trending-roles-in-the-pharma-biotech-industry
- Adrien Laurent, on behalf of Intuition Labs (last updated March 21, 2026). “Pharma’s AI Skills Gap: A 2025 Data-Driven Analysis.” Accessed online at https://intuitionlabs.ai/articles/pharma-ai-skills-gap
- Tech Council of Australia (June 2024). “Meeting the AI Skills Boom.” Accessed online at https://techcouncil.com.au/wp-content/uploads/Meeting-the-AI-Skills-Boom-2024.v2.pdf
- Anthropic (March 31, 2026). “Australian government and Anthropic sign MOU for AI safety and research.” Access online at https://www.anthropic.com/news/australia-MOU
- BiotechDispatch (March 30, 2026). “Ai meets oncology as Algorae advances drug discovery collaboration.” Access online at https://biotechdispatch.com.au/news/ai-meets-oncology-as-algorae-advances-drug-discovery-collaboration
